Search Result

Results for "

BH3-domain

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Bcl-2 Family (13) Beclin1 (1) NADPH Oxidase (3)
By Research Areas:	Cancer (10) Neurological Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-P5328

Noxa A BH3	NADPH Oxidase	Others
Noxa A BH3 is a biological active peptide. (BH3 domain of Noxa protein)

HY-P5342

Hrk BH3	Bcl-2 Family	Others
Hrk BH3 is a biological active peptide. (BH3 domain of Hrk)

HY-P1562

PUMA BH3	Bcl-2 Family	Cancer
PUMA BH3 is a p53 upregulated modulator of apoptosis (PUMA) BH3 domain peptide, acts as a direct activator of Bak, with a K_d of 26 nM.

HY-P2499A

BAD (103-127) (human), FAM-labeled TFA	Bcl-2 Family	Cancer
BAD (103-127) (human), FAM-labeled TFA is a FAM-labeled human BAD (103-127) (HY-P2468). BAD (103-127) (human) TFA, the 25-mer Bad peptide, is derived from the BH3 domain of BAD and can antagonize the function of Bcl-xL .

HY-P2468

BAD (103-127) (human) BADBH3 103-127 (human); BADBH3 (human)	Bcl-2 Family	Cancer
BAD (103-127) (human), the 25-mer Bad peptide, is derived from the BH3 domain of BAD, can antagonize the function of Bcl-xL. BAD (103-127) (human) is reported to have almost 800-fold higher affinity for Bcl-XL than the 16-mer peptide .

HY-P0300

Bak BH3	Bcl-2 Family	Cancer
Bak BH3 is derived from the BH3 domain of Bak, can antagonize the function of Bcl-xL in cells.

HY-149681

Beclin1-Bcl-2 interaction inhibitor 1	Bcl-2 Family Beclin1	Neurological Disease Cancer
Beclin1-Bcl-2 interaction inhibitor 1 is a Beclin1 and Bcl-2 interaction inhibitor with an IC₅₀ value of 4.4 nM. Beclin1-Bcl-2 interaction inhibitor 1 disrupts the binding of the Bcl-2-Beclin 1 BH3 domain. Beclin1-Bcl-2 interaction inhibitor 1 can be used in the research of cancer and neurodegenerative diseases .

HY-161276

BFC1108 1 Publications Verification	Apoptosis Bcl-2 Family	Cancer
BFC1108 is a small molecule Bcl-2 functional converter. BFC1108 induces a conformational change in Bcl-2, resulting in the exposure of its BH3 domain both in vitro and in vivo. BFC1108 effectively induces apoptosis in Bcl-2 expressing cancers. .

HY-P5341

Bik BH3	Bcl-2 Family	Others
Bik BH3 is a biological active peptide. (BH3 domain of BIK)

HY-P5330

Noxa B BH3	NADPH Oxidase	Others
Noxa B BH3 is a biological active peptide. (BH3 domain of Noxa protein)

HY-P1562A

PUMA BH3 TFA	Bcl-2 Family	Cancer
PUMA BH3 TFA is a p53 upregulated modulator of apoptosis (PUMA) BH3 domain peptide, acts as a direct activator of Bak, with a K_d of 26 nM .

HY-P5324

Bad BH3 (mouse)	Bcl-2 Family	Others
Bad BH3 (mouse) is a biological active peptide. (This is a bcl-2 binding peptide. This peptide is derived from the BH3 domain (a death domain) of Bad, amino acid residues 140 to 165.)

HY-P2499

BAD (103-127) (human), FAM-labeled	Bcl-2 Family	Cancer
BAD (103-127) (human), FAM-labeled is a FAM-labeled human BAD (103-127) (HY-P2468). BAD (103-127) (human), the 25-mer Bad peptide, is derived from the BH3 domain of BAD and can antagonize the function of Bcl-xL .

HY-P5329

r8-Gly-Noxa A BH3	NADPH Oxidase	Others
r8-Gly-Noxa A BH3 is a biological active peptide. (This cell permeable peptide is derived from the BH3 domain (a death domain) of Noxa A, amino acid residues 17 to 36. Eight D-Arginine residues and a Glycine linker residue are added to the amino terminal of the peptide.)

HY-161732

GQN-B37-E	Bcl-2 Family	Cancer
GQN-B37-E is a potent selective binder and inhibitor of MCL-1. GQN-B37-E binds to the BH3-domain-binding pocket in MCL-1. GQN-B37-E exhibits binding affinity for MCL-1 at the submicromolar range (K_i = 0.6 μM) without apparent binding to BCL-2 or BCL-XL .

HY-N9826

Icterogenin	Bcl-2 Family	Cancer
Icterogenin is a selective inhibitor targeting the Bcl-XL/Bak BH3 domain peptide interaction and exhibits anti-leukemic activity. Icterogenin regulates protein interactions and affects tumor cell survival. Icterogenin is an oleanane-type triterpenoid compound that can be isolated from Lantana camara and is useful in the field of anti-tumor drug development .

Cat. No.	상품명	Target	Research Area

HY-P5328

Noxa A BH3	NADPH Oxidase	Others
Noxa A BH3 is a biological active peptide. (BH3 domain of Noxa protein)

HY-P5342

Hrk BH3	Bcl-2 Family	Others
Hrk BH3 is a biological active peptide. (BH3 domain of Hrk)

HY-P1562

PUMA BH3	Bcl-2 Family	Cancer
PUMA BH3 is a p53 upregulated modulator of apoptosis (PUMA) BH3 domain peptide, acts as a direct activator of Bak, with a K_d of 26 nM.

HY-P2499A

BAD (103-127) (human), FAM-labeled TFA	Bcl-2 Family	Cancer
BAD (103-127) (human), FAM-labeled TFA is a FAM-labeled human BAD (103-127) (HY-P2468). BAD (103-127) (human) TFA, the 25-mer Bad peptide, is derived from the BH3 domain of BAD and can antagonize the function of Bcl-xL .

HY-P2468

BAD (103-127) (human) BADBH3 103-127 (human); BADBH3 (human)	Bcl-2 Family	Cancer
BAD (103-127) (human), the 25-mer Bad peptide, is derived from the BH3 domain of BAD, can antagonize the function of Bcl-xL. BAD (103-127) (human) is reported to have almost 800-fold higher affinity for Bcl-XL than the 16-mer peptide .

HY-P0300

Bak BH3	Bcl-2 Family	Cancer
Bak BH3 is derived from the BH3 domain of Bak, can antagonize the function of Bcl-xL in cells.

HY-P5341

Bik BH3	Bcl-2 Family	Others
Bik BH3 is a biological active peptide. (BH3 domain of BIK)

HY-P5330

Noxa B BH3	NADPH Oxidase	Others
Noxa B BH3 is a biological active peptide. (BH3 domain of Noxa protein)

HY-P1562A

PUMA BH3 TFA	Bcl-2 Family	Cancer
PUMA BH3 TFA is a p53 upregulated modulator of apoptosis (PUMA) BH3 domain peptide, acts as a direct activator of Bak, with a K_d of 26 nM .

HY-P5324

Bad BH3 (mouse)	Bcl-2 Family	Others
Bad BH3 (mouse) is a biological active peptide. (This is a bcl-2 binding peptide. This peptide is derived from the BH3 domain (a death domain) of Bad, amino acid residues 140 to 165.)

HY-P2499

BAD (103-127) (human), FAM-labeled	Bcl-2 Family	Cancer
BAD (103-127) (human), FAM-labeled is a FAM-labeled human BAD (103-127) (HY-P2468). BAD (103-127) (human), the 25-mer Bad peptide, is derived from the BH3 domain of BAD and can antagonize the function of Bcl-xL .

HY-P5329

r8-Gly-Noxa A BH3	NADPH Oxidase	Others
r8-Gly-Noxa A BH3 is a biological active peptide. (This cell permeable peptide is derived from the BH3 domain (a death domain) of Noxa A, amino acid residues 17 to 36. Eight D-Arginine residues and a Glycine linker residue are added to the amino terminal of the peptide.)

Icterogenin	Structural Classification Terpenoids Verbenaceae Plants Pentacyclic Triterpenoids Lantana camaraLinn. Source Classification	Bcl-2 Family
Icterogenin is a selective inhibitor targeting the Bcl-XL/Bak BH3 domain peptide interaction and exhibits anti-leukemic activity. Icterogenin regulates protein interactions and affects tumor cell survival. Icterogenin is an oleanane-type triterpenoid compound that can be isolated from Lantana camara and is useful in the field of anti-tumor drug development .

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
이메일 *

	Sorry, but the email address you supplied was invalid.

BH3-domain

Inhibitors & Agonists

Peptides

NaturalProducts

Natural
Products